ArticleBone & joint research2026
OX40L in endothelial cells promotes temporomandibular joint subchondral bone angiogenesis and osteoclastogenesis in mice.
Article in Bone & joint research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Aims: Subchondral vascular proliferation is a substantial pathological manifestation of temporomandibular joint osteoarthritis (TMJOA), yet its underlying mechanisms remain unclear. This study aimed to investigate the role of OX40-OX40L signalling in mediating subchondral angiogenesis and osteoclastogenesis in early stage TMJOA. Methods: A unilateral anterior cross-bite (UAC) model was established in mice to induce TMJOA, and the expression of OX40L in subchondral vessels was examined at the early stages of the disease. In vitro, the OX40-OX40L pathway was activated in bone microvascular endothelial cells (BMECs) to assess its effects on cell migration, tube formation, and osteoclast differentiation. An OX40L monoclonal antibody was used during in vivo experiments to block this signalling pathway. Results: We observed increased expression of OX40L in the subchondral vessels during early TMJOA, accompanied by significant bone destruction. OX40L activation enhanced endothelial cell migration and angiogenesis in vitro, whereas pathway inhibition reversed these effects and reduced osteoclast differentiation. In vivo, OX40L monoclonal antibody effectively alleviated subchondral angiogenesis and osteoclastogenesis. Conclusion: Endothelial OX40L signalling promotes pathological subchondral angiogenesis and osteoclastogenesis in early TMJOA.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.